Table 1.
Patient characteristics.
| Characteristics | N (%)/median (IQRa) |
|---|---|
| Gender | |
| Male | 61(89.7%) |
| Female | 7(10.3%) |
| Age | 58 (46–63) |
| <60 | 37(54.4%) |
| ≥60 | 31(45.6%) |
| Aetiology of liver disease | |
| Hepatitis B | 66(97.1%) |
| Hepatitis C | 2(2.9%) |
| ECOG statusa | |
| 0 | 20(29.4%) |
| 1 | 35(51.5%) |
| 2 | 13(19.1%) |
| Inside of Milan | 15(22.1%) |
| Outside of Milan | 53(77.9%) |
| Maximum tumor diameter | |
| <5 cm | 39(57.4%) |
| ≥5 cm | 29(42.65) |
| BCLC classificationa | |
| A | 10(14.7%) |
| B | 10(14.7%) |
| C | 36(52.9%) |
| D | 12(17.6%) |
| PVTTa | |
| No | 23(33.8%) |
| Yes | 45(66.2%) |
| Number of tumors | |
| Single | 23(33.8%) |
| Multiple | 45(66.2%) |
| MELDa | 12.0 (10.0–14.0) |
| <15 | 53(77.9%) |
| ≥15 | 14(20.6%) |
| Symptomatic portal hypertension | |
| Refractory ascites | 68(100.0%) |
| Variceal bleeding | 13(19.1%) |
| Gastrointestinal symptoms | 2(2.9%) |
| Laboratory tests | |
| Platelets [109/L] | 87 (62–133) |
| INRa | 1.31 (1.16–1.49) |
| AST [U/L]a | 50.80 (37.80–69.5) |
| ALT [U/L]a | 38.90 (25.53–51.93) |
| Albumin [g/dL] | 34.30 (32.15–37.30) |
| Creatinine [mg/dL] | 73.60(61.98–91.98) |
| Bilirubin [mg/dL] | 30.50(22.28–40.63) |
| AFP [ng/mL]a | |
| <400 | 48(70.6%) |
| ≥400 | 20(29.4%) |
a
ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombosis; MELD, model of endstage liver disease; INR, international normalised ratio; AST, aspartate aminotransferase; ALT, alanine transaminase; AFP, alpha fetoprotein; IQR, interquartile range.